TAK - Good News For Sleep Disorder Patients - Takeda's Therapy Shows Promise In Mid-Stage Study | Benzinga
Thursday after close, Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results from a Phase 2b trial evaluating TAK-861, an oral orexin receptor 2 (OX2R) agonist, in patients with narcolepsy type 1.
Narcolepsy is a chronic, rare neurological disorder of central hypersomnolence (excessive daytime sleepiness) classified into two different types:
- Narcolepsy type 1 (NT1) is caused by a significant loss of orexin neurons with a resulting lack of orexin.
- Narcolepsy type 2 (NT2), where orexin levels are generally normal.
Two separate Phase 2b studies were conducted in ...